Technical Analysis for CVAC - CureVac N.V.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| NR7 | Range Contraction | 2.90% | |
| Stochastic Reached Overbought | Strength | 2.90% | |
| Weak + Overbought | Other | 2.90% | |
| Wide Bands | Range Expansion | 2.90% | |
| Weak, Overbought and Reversal Signs | Reversal | 2.90% | |
| Gapped Up | Strength | 2.90% |
| Alert | Time |
|---|---|
| Upper Bollinger Band Resistance | about 22 hours ago |
| Rose Above Upper Bollinger Band | about 22 hours ago |
| Up 5% | about 22 hours ago |
| Rose Above Previous Day's High | about 22 hours ago |
| Up 3% | about 22 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 06/18/2024
CureVac N.V. Description
CureVac B.V., a clinical-stage biopharmaceutical company, engages in developing medicines based on messenger ribonucleic acid. The company's lead clinical programs include CV8102 that is in a Phase I clinical trial for the treatment of various types of solid tumors; and CV7202, which is investigating in a Phase I clinical trial for vaccination against rabies. It is also advancing mRNA vaccine program against coronavirus (SARS-CoV-2), which is in Phase I clinical trial. The company has collaboration and license agreements with GlaxoSmithKline Biologicals SA, Genmab B.V., Boehringer Ingelheim GmbH, and Eli Lilly and Company; development and option agreements with Arcturus Therapeutics, Inc., Acuitas Therapeutics Inc., and CRISPR Therapeutics AG; and a development and intellectual property agreement with Tesla Grohmann Automation GmbH. CureVac B.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Pharmaceutical Solid Tumors Acid Health Care Coronavirus Vaccination CRISPR Rabies Arcturus Therapeutics Genmab
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 12.36 |
| 52 Week Low | 2.215 |
| Average Volume | 742,962 |
| 200-Day Moving Average | 5.06 |
| 50-Day Moving Average | 2.93 |
| 20-Day Moving Average | 2.74 |
| 10-Day Moving Average | 2.99 |
| Average True Range | 0.19 |
| RSI (14) | 61.83 |
| ADX | 24.51 |
| +DI | 28.26 |
| -DI | 14.10 |
| Chandelier Exit (Long, 3 ATRs) | 2.72 |
| Chandelier Exit (Short, 3 ATRs) | 2.78 |
| Upper Bollinger Bands | 3.28 |
| Lower Bollinger Band | 2.19 |
| Percent B (%b) | 0.91 |
| BandWidth | 40.08 |
| MACD Line | 0.06 |
| MACD Signal Line | -0.01 |
| MACD Histogram | 0.0682 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.47 | ||||
| Resistance 3 (R3) | 3.47 | 3.38 | 3.43 | ||
| Resistance 2 (R2) | 3.38 | 3.31 | 3.38 | 3.41 | |
| Resistance 1 (R1) | 3.29 | 3.27 | 3.33 | 3.28 | 3.39 |
| Pivot Point | 3.19 | 3.19 | 3.22 | 3.19 | 3.19 |
| Support 1 (S1) | 3.10 | 3.12 | 3.15 | 3.10 | 2.99 |
| Support 2 (S2) | 3.00 | 3.08 | 3.00 | 2.97 | |
| Support 3 (S3) | 2.91 | 3.00 | 2.95 | ||
| Support 4 (S4) | 2.91 |
